Nataliya V. Uboha, MD, PhD

Nataliya Uboha, MD, PhD, a medical oncologist at University of Wisconsin Health, as well as an associate professor and researcher in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health

Articles

Key Takeaways and Future Questions in Perioperative GC/GEJC

August 1st 2025

Panelists discuss the key takeaways, including the establishment of durvalumab plus FLOT as the new standard requiring proper laparoscopic staging and multidisciplinary care. Future questions focus on optimizing treatment for nonresponders and developing more personalized therapeutic approaches.

Future of Perioperative IO + FLOT Chemotherapy in GC/GEJC

July 25th 2025

Panelists discuss how perioperative immunotherapy (IO) will serve as the foundation for future therapeutic advances, with potential directions including biomarker-driven personalized treatment, organ preservation strategies for complete responders, and integration of novel targeted therapies into the treatment paradigm.

Multidisciplinary Collaboration for Perioperative IO in GC/GEJC

July 25th 2025

Panelists discuss how successful implementation of durvalumab plus FLOT requires enhanced multidisciplinary coordination involving oncologists, surgeons, pharmacists, nurses, and nutritionists to optimize patient outcomes and manage the complexities of perioperative care.

From Trial to Practice: Considerations for Delivering FLOT + IO to Patients

July 18th 2025

Panelists discuss how adding durvalumab to FLOT does not significantly increase toxicity profiles and can be safely delivered using standard oncology practices with appropriate dose modifications, nutritional support, and multidisciplinary care coordination.

Redefining the Standard: Impact of MATTERHORN on the GC/GEJC Landscape

July 18th 2025

Panelists discuss how MATTERHORN establishes durvalumab plus FLOT as the new standard of care for all patients with resectable gastric cancers (GC) and gastroesophageal junction cancers (GEJC) who are candidates for curative-intent surgery, with plans to implement this regimen immediately upon regulatory approval.

Checkpoint Inhibitors In GC/GEJC: Trials Across the Landscape

July 11th 2025

Panelists discuss how other immunotherapy trials in the perioperative setting, including studies with pembrolizumab and atezolizumab, have shown mixed results, with improved pathologic responses not necessarily translating to survival benefits. They note the negative results from the adjuvant CheckMate 577 trial.

Surgical Considerations With IO In Perioperative GC/GEJC

July 11th 2025

Panelists discuss how adding immunotherapy (IO) to perioperative chemotherapy does not appear to complicate surgical procedures or compromise the ability to achieve negative margins, with R0 resection rates remaining unchanged between treatment arms in the MATTERHORN trial.

Interpreting MATTERHORN: Perspectives on Perioperative Durvalumab + FLOT in GC/GEJC

July 2nd 2025

Panelists discuss how the MATTERHORN results represent a practice-changing advancement that they are ready to implement clinically, with improved pathologic complete response rates and event-free survival providing confidence in the regimen’s efficacy across most patient subgroups except those with microsatellite instability–high (MSI-H) tumors.

Key Updates From MATTERHORN: Perioperative Durvalumab + FLOT in GC/GEJC

July 2nd 2025

Panelists discuss how the MATTERHORN trial successfully demonstrated that adding durvalumab immunotherapy to perioperative FLOT chemotherapy significantly improved event-free survival with an 8-percentage point improvement at 24 months, representing a clear advancement in the treatment paradigm.

Perioperative Therapy In GC/GEJC: Challenges and Unmet Needs

June 25th 2025

Panelists discuss how perioperative FLOT chemotherapy has simplified treatment decisions but presents toxicity challenges for patients with comorbidities, while emphasizing the critical importance of laparoscopic staging and acknowledging that current approaches still fail to cure approximately half of patients.

Understanding GC/GEJC: Disease Overview and Current Treatment Practices

June 25th 2025

Panelists discuss how gastric cancers (GC) and gastroesophageal junction cancers (GEJC) present with nonspecific symptoms, affect approximately 1.2 million patients worldwide annually, and are managed with perioperative FLOT chemotherapy as the established standard of care for resectable disease.

Dr Uboha on the Role of Biomarkers for Guiding Esophageal Adenocarcinoma Treatment Selection

May 8th 2025

Nataliya Uboha, MD, PhD, discusses how biomarkers help guide treatment decision-making in esophageal adenocarcinoma.

FDA Approval Insights: Tislelizumab Plus Chemo in Unresectable Metastatic ESCC: With Nataliya Uboha, MD, PhD

March 13th 2025

Nataliya Uboha, MD, PhD, discusses the FDA approval of first-line tislelizumab-jsgr with platinum-containing chemotherapy for unresectable or metastatic ESCC.

Dr Uboha on the FDA Approval of First-Line Tislelizumab Plus Chemotherapy for Metastatic ESCC

March 7th 2025

Nataliya Uboha, MD, PhD, discusses how the FDA approval of tislelizumab plus chemotherapy​ addresses unmet needs for patients with metastatic ESCC.

ESMO 2021 Updates in Gastric Cancer and Colorectal Cancer

December 6th 2021

Sam Klempner, MD; Daniel H. Ahn, DO; Nataliya V. Uboha, MD, PhD; and Manish A. Shah, MD, FASCO, review recent updates in second-line gastric cancer, CAR T-cell therapy in solid tumors, and colorectal cancer presented at ESMO 2021.

ESMO 2021 Updates in HER2+ Metastatic Gastric and Gastroesophageal Cancer

November 29th 2021

Key opinion leaders in gastric cancers comment on ESMO 2021 updates in metastatic HER2+ esophagogastric adenocarcinoma and metastatic HER2+ gastric or gastroesophageal junction cancer.

ESMO 2021 Updates in Gastroesophageal and Gastric Adenocarcinomas

November 22nd 2021

Drs Sam Klempner, Nataliya V. Uboha, Daniel H. Ahn, and Manish A. Shah discuss recent data presented at ESMO 2021 for metastatic or locally advanced gastroesophageal and gastric adenocarcinomas.

ESMO 2021 Updates in Metastatic Esophageal Squamous Cell Carcinoma

November 15th 2021

Experts in gastrointestinal cancers review recent updates and clinical implications from phase 3 trials presented at ESMO 2021 in metastatic esophageal squamous cell carcinoma (ESCC).

Defining Oligometastatic Gastroesophageal Cancer May Provide Clarity for Treatment Advances

June 30th 2021

The debate continues as to how to define oligometastatic disease and whether it represents a unique stage between limited-stage and widely metastatic disease.

Dr. Uboha on Early Efficacy Data With Zanidatamab in HER2+ Upper GI Cancers

May 5th 2021

Nataliya V. Uboha, MD, PhD, discusses early efficacy data demonstrated with zanidatamab in HER2-expressing upper gastrointestinal cancers.